Zkusit zdarma
IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc.

IDYA
Cena:
$ 29.10
-0.44 (-1.49%)
Valuace
70
Růst
0
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
IDEAYA Biosciences, Inc. (IDYA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

IDEAYA Biosciences, Inc. (IDYA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

22:00 12-05-2026

IDEAYA Biosciences, Inc. (IDYA) Presents at Bank of America Global Healthcare Conference 2026 Transc...

IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates

IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates

8:11 05-05-2026

IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $1.11 per share versus the Zacks C...

IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

6:00 05-05-2026

Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint; co...

IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program

IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program

6:00 30-04-2026

Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint and...

IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma

IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma

10:15 21-04-2026

SOUTH SAN FRANCISCO, Calif., April 21, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA),...

IDEAYA Biosciences Unveils OptimUM-02 Data: Darovasertib/Crizotinib Doubles PFS in Uveal Melanoma

IDEAYA Biosciences Unveils OptimUM-02 Data: Darovasertib/Crizotinib Doubles PFS in Uveal Melanoma

1:02 14-04-2026

IDEAYA Biosciences (NASDAQ: IDYA) shared top-line results from its randomized phase II/III OptimUM-0...

IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma Transcript

IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma Transcript

12:11 13-04-2026

IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovaser...

IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars

IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars

7:48 13-04-2026

IDEAYA shares rise after darovasertib trial shows progression-free survival benefit in uveal melanom...

Ideaya Biosciences Stock Jumps 15% on Eye Cancer Therapy Trial Results

Ideaya Biosciences Stock Jumps 15% on Eye Cancer Therapy Trial Results

7:21 13-04-2026

The California-based biotechnology company reports statistically significant results from a clinical...

IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma

IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma

6:00 13-04-2026

Trial met the primary endpoint showing statistically significant improvement in median PFS by BICR, ...

IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026

IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026

16:05 10-04-2026

SOUTH SAN FRANCISCO, Calif., April 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA),...

Ideaya Biosciences: Key Pivotal Data Imminent

Ideaya Biosciences: Key Pivotal Data Imminent

5:04 08-04-2026

Ideaya Biosciences is on the verge of a pivotal data readout for darovasertib, its lead uveal melano...

IDEAYA Biosciences Target of Unusually Large Options Trading (NASDAQ:IDYA)

IDEAYA Biosciences Target of Unusually Large Options Trading (NASDAQ:IDYA)

1:25 07-04-2026

IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report) was the target of unusually large options ...

IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial

IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial

10:00 22-03-2026

SOUTH SAN FRANCISCO, Calif., March 22, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA),...

Brokerages Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Target Price at $48.69

Brokerages Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Target Price at $48.69

1:31 21-03-2026

IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report) has been assigned an average recommendatio...

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update

6:00 09-03-2026

Potential best-in-class profile, including ~1,400-fold selective binding to MTA-PRMT5 versus SAM-PRM...

IDEAYA Biosciences, Inc. (IDYA) Discusses Pipeline Progress and Upcoming Data Readout in Uveal Melanoma and ADC Programs Transcript

IDEAYA Biosciences, Inc. (IDYA) Discusses Pipeline Progress and Upcoming Data Readout in Uveal Melanoma and ADC Programs Transcript

18:25 23-02-2026

IDEAYA Biosciences, Inc. (IDYA) Discusses Pipeline Progress and Upcoming Data Readout in Uveal Melan...

IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer

IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer

6:00 23-02-2026

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), ...

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

4:42 21-02-2026

IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report) has received a consensus recommendation of...

IDEAYA Biosciences, Inc. (IDYA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

IDEAYA Biosciences, Inc. (IDYA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

15:44 18-02-2026

IDEAYA Biosciences, Inc. (IDYA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcrip...

close

IDEAYA BIOSCIENCES TO PARTICIPATE IN UPCOMING FEBRUARY 2026 INVESTOR RELATIONS EVENTS

02-02-2026
SOUTH SAN FRANCISCO, CALIF., FEB. 2, 2026 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA), A...
Více zde

IDEAYA BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

30-01-2026
SOUTH SAN FRANCISCO, CALIF., JAN. 30, 2026 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA), ...
Více zde

IDEAYA BIOSCIENCES PROVIDES A BUSINESS UPDATE AND OUTLINES 2026 CORPORATE OBJECTIVES AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

11-01-2026
SOUTH SAN FRANCISCO, CALIF., JAN. 11, 2026 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA),...
Více zde

IDEAYA BIOSCIENCES ANNOUNCES PARTICIPATION AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

05-01-2026
SOUTH SAN FRANCISCO, CALIF., JAN. 5, 2026 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA), A...
Více zde

IDEAYA BIOSCIENCES COMPLETES TARGETED FULL ENROLLMENT IN RANDOMIZED PIVOTAL PHASE 2/3 TRIAL (OPTIMUM-02) OF DAROVASERTIB IN COMBINATION WITH CRIZOTINIB IN FIRST-LINE HLA*A2-NEGATIVE METASTATIC UVEAL MELANOMA

11-12-2025
TARGETED ENROLLMENT OF 435 PATIENTS TO ENABLE POTENTIAL FULL APPROVAL FILING HAS BEEN COMPLETED IN O...
Více zde

IDEAYA BIOSCIENCES ANNOUNCES IND SUBMISSION FOR IDE574, A POTENTIAL FIRST-IN-CLASS KAT6/7 DUAL INHIBITOR FOR BREAST AND LUNG CANCERS

10-12-2025
PHASE 1 DOSE ESCALATION TRIAL OF MONOTHERAPY IDE574 EXPECTED TO BEGIN IN 1Q 2026 TARGETING TO PRESE...
Více zde

IDE034, A BISPECIFIC ADC LICENSED BY BIOCYTOGEN TO IDEAYA, RECEIVES FDA IND CLEARANCE

04-12-2025
BEIJING--(BUSINESS WIRE)--BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. (BIOCYTOGEN, HKEX: 02315), ...
Více zde

IDEAYA BIOSCIENCES ANNOUNCES IND CLEARANCE FOR IDE034, A POTENTIAL FIRST-IN-CLASS BISPECIFIC B7H3/PTK7 TOP1 ADC TARGETING MULTIPLE SOLID TUMOR TYPES

01-12-2025
B7H3 AND PTK7 IS CO-EXPRESSED IN MULTIPLE SOLID TUMOR TYPES, INCLUDING LUNG, COLORECTAL, AND HEAD AN...
Více zde

IDEAYA BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

28-11-2025
SOUTH SAN FRANCISCO, CALIF. , NOV. 28, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA),...
Více zde

IDEAYA BIOSCIENCES TO PARTICIPATE IN UPCOMING DECEMBER 2025 INVESTOR RELATIONS EVENTS

24-11-2025
SOUTH SAN FRANCISCO, CALIF. , NOV. 24, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA)...
Více zde

IDEAYA BIOSCIENCES REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

04-11-2025
PHASE 2/3 TRIAL (OPTIMUM-02) OF THE DAROVASERTIB/CRIZOTINIB COMBINATION IN 1L HLA*A2-NEGATIVE METAS...
Více zde

IDEAYA BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

31-10-2025
SOUTH SAN FRANCISCO, CALIF. , OCT. 31, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA),...
Více zde

IDEAYA BIOSCIENCES TO PARTICIPATE IN UPCOMING NOVEMBER 2025 INVESTOR RELATIONS EVENTS

27-10-2025
SOUTH SAN FRANCISCO, CALIF. , OCT. 27, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA)...
Více zde

IDEAYA BIOSCIENCES ANNOUNCES POSITIVE PHASE 2 DATA FOR DAROVASERTIB IN THE NEOADJUVANT SETTING OF PRIMARY UVEAL MELANOMA IN A PROFFERED PAPER ORAL PRESENTATION AT ESMO 2025

20-10-2025
83% (78/94) OF PATIENTS DEMONSTRATED OCULAR TUMOR SHRINKAGE, WITH 54% (51/94) ACHIEVING ≥20% TUMOR...
Více zde

IDEAYA BIOSCIENCES REPORTS POSITIVE MEDIAN OVERALL SURVIVAL DATA FROM PHASE 2 TRIAL OF THE DAROVASERTIB AND CRIZOTINIB COMBINATION IN FIRST-LINE METASTATIC UVEAL MELANOMA AT THE 2025 SOCIETY FOR MELANOMA RESEARCH CONGRESS

20-10-2025
COMBINATION DEMONSTRATED MEDIAN OVERALL SURVIVAL (OS) OF 21.1 MONTHS, COMPARED TO REPORTED HISTORICA...
Více zde

IDEAYA BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

26-09-2025
SOUTH SAN FRANCISCO, CALIF. , SEPT. 26, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA...
Více zde

IDEAYA BIOSCIENCES ANNOUNCES POSITIVE DATA FROM PHASE 1/2 COMBINATION TRIAL OF IDE397, A POTENTIAL FIRST-IN-CLASS MAT2A INHIBITOR, AND TRODELVY® IN MTAP-DELETION UROTHELIAL CANCER

08-09-2025
OVERALL RESPONSE RATE (ORR) OF 57% (4/7; 3CPR+1UPR) IN PATIENTS TREATED WITH A COMBINATION OF 30 MG ...
Více zde

IDEAYA BIOSCIENCES ANNOUNCES POSITIVE INTERIM PHASE 2 DATA FOR DAROVASERTIB IN THE NEOADJUVANT SETTING OF PRIMARY UVEAL MELANOMA

08-09-2025
TREATMENT WITH DAROVASERTIB RESULTED IN ROBUST OCULAR TUMOR SHRINKAGE, LOWER SIMULATED RADIATION DOS...
Více zde

IDEAYA BIOSCIENCES AND HENGRUI PHARMA PRESENT POSITIVE PHASE 1 DATA FOR IDE849 (SHR-4849), A POTENTIAL FIRST-IN-CLASS DLL3 TOP1 ADC, IN SMALL CELL LUNG CANCER AT THE IASLC 2025 WORLD CONFERENCE ON LUNG CANCER

07-09-2025
80.0% (8/10) ORR AND 70.0% (7/10) CONFIRMED ORR IN 2L SCLC; A 73.7% (14/19) ORR AND 57.9% (11/19) CO...
Více zde

IDEAYA BIOSCIENCES ANNOUNCES FIRST-PATIENT-IN FOR PHASE 1/2 COMBINATION TRIAL OF IDE397, A POTENTIAL FIRST-IN-CLASS MAT2A INHIBITOR, AND TRODELVY® IN MTAP-DELETION NON-SMALL CELL LUNG CANCER

04-09-2025
SOUTH SAN FRANCISCO, CALIF. , SEPT. 4, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA),...
Více zde

IDEAYA BIOSCIENCES ANNOUNCES IND SUBMISSION FOR IDE892, A POTENTIAL BEST-IN-CLASS PRMT5 INHIBITOR FOR MTAP-DELETION SOLID TUMORS

03-09-2025
DOSING OF FIRST PATIENT IN PHASE 1 DOSE ESCALATION TRIAL OF IDE892 TARGETED IN 4Q 2025 PRECLINICAL P...
Více zde

SERVIER AND IDEAYA BIOSCIENCES PARTNER TO BRING DAROVASERTIB, A PROMISING UVEAL MELANOMA TREATMENT, TO PATIENTS WORLDWIDE

02-09-2025
SERVIER AND IDEAYA BIOSCIENCES ENTER INTO AN EXCLUSIVE LICENSE AGREEMENT FOR REGULATORY AND COMMERCI...
Více zde

IDEAYA BIOSCIENCES TO PRESENT FIRST MEDIAN OVERALL SURVIVAL DATA FROM PHASE 2 TRIAL OF THE DAROVASERTIB / CRIZOTINIB COMBINATION IN METASTATIC UVEAL MELANOMA AT THE 2025 SOCIETY FOR MELANOMA RESEARCH CONGRESS

29-08-2025
SOUTH SAN FRANCISCO, CALIF. , AUG. 29, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA)...
Více zde

IDEAYA BIOSCIENCES TO PARTICIPATE IN UPCOMING SEPTEMBER 2025 INVESTOR RELATIONS EVENTS

25-08-2025
SOUTH SAN FRANCISCO, CALIF. , AUG. 25, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA)...
Více zde

IDEAYA BIOSCIENCES ANNOUNCES AGENDA FOR 10-YEAR ANNIVERSARY R&D DAY ON SEPTEMBER 8, 2025

18-08-2025
SOUTH SAN FRANCISCO, CALIF. , AUG. 18, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA),...
Více zde

IDEAYA BIOSCIENCES, INC. REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

05-08-2025
PHASE 2/3 TRIAL OF THE DAROVASERTIB AND CRIZOTINIB COMBINATION IN 1L HLA-A2-NEGATIVE METASTATIC UVEA...
Více zde

IDEAYA BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

01-08-2025
SOUTH SAN FRANCISCO, CALIF. , AUG. 1, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA), ...
Více zde

IDEAYA BIOSCIENCES ANNOUNCES PROFFERED PAPER ORAL PRESENTATION AT ESMO 2025 FOR PHASE 2 CLINICAL TRIAL OF NEOADJUVANT DAROVASERTIB IN PRIMARY UVEAL MELANOMA

24-07-2025
THE PRESENTATION WILL INCLUDE DATA FROM OVER 90 PATIENTS IN BOTH THE PLAQUE BRACHYTHERAPY AND ENUCLE...
Více zde

IDEAYA BIOSCIENCES ANNOUNCES 10-YEAR ANNIVERSARY R&D DAY ON SEPTEMBER 8, 2025 TO PRESENT MULTIPLE CLINICAL DATA UPDATES AND OUTLINE FUTURE GROWTH STRATEGY

23-07-2025
SOUTH SAN FRANCISCO, CALIF. , JULY 23, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA),...
Více zde

IDEAYA BIOSCIENCES AND HENGRUI PHARMACEUTICALS ANNOUNCE ORAL PRESENTATION AT IASLC 2025 WORLD CONFERENCE ON LUNG CANCER FOR IDE849 (SHR-4849), A POTENTIAL FIRST-IN-CLASS DLL3-TOP1 ADC

22-07-2025
CLINICAL EFFICACY AND SAFETY DATA WILL BE PRESENTED FROM OVER 70 SMALL-CELL LUNG CANCER (SCLC) PATIE...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-01-12 00:00:008-KStáhnout
2025-12-12 00:00:008-KStáhnout
2025-12-05 00:00:008-KStáhnout
2025-11-04 00:00:008-KStáhnout
2025-11-04 00:00:0010-QStáhnout
2025-10-20 01:00:008-KStáhnout
2025-10-20 00:00:008-KStáhnout
2025-09-08 01:00:008-KStáhnout
2025-09-08 00:00:008-KStáhnout
2025-09-02 01:00:008-KStáhnout
2025-09-02 00:00:008-KStáhnout
2025-08-05 01:00:008-KStáhnout
2025-08-05 01:00:0010-QStáhnout
2025-08-05 00:00:008-KStáhnout
2025-08-05 00:00:0010-QStáhnout
2025-06-27 01:00:008-KStáhnout
2025-06-27 00:00:008-KStáhnout
2025-06-24 01:00:008-KStáhnout
2025-06-24 00:00:008-KStáhnout
2025-05-06 01:00:008-KStáhnout
2025-05-06 01:00:0010-QStáhnout
2025-05-06 00:00:008-KStáhnout
2025-05-06 00:00:0010-QStáhnout
2025-04-02 01:00:008-KStáhnout
2025-04-02 00:00:008-KStáhnout
2025-02-18 00:00:0010-KStáhnout
2025-02-17 23:00:0010-KStáhnout
2025-02-13 00:00:008-KStáhnout
2025-02-12 23:00:008-KStáhnout
2025-02-10 00:00:008-KStáhnout
2025-02-09 23:00:008-KStáhnout
2024-12-30 00:00:008-KStáhnout
2024-12-29 23:00:008-KStáhnout
2024-11-04 00:00:008-KStáhnout
2024-11-04 00:00:0010-QStáhnout
2024-11-03 23:00:008-KStáhnout
2024-11-03 23:00:0010-QStáhnout
2024-10-25 01:00:008-KStáhnout
2024-10-25 00:00:008-KStáhnout
2024-10-04 01:00:008-KStáhnout
2024-10-04 00:00:008-KStáhnout
2024-09-23 01:00:008-KStáhnout
2024-09-23 00:00:008-KStáhnout
2024-08-06 01:00:008-KStáhnout
2024-08-06 01:00:0010-QStáhnout
2024-08-06 00:00:008-KStáhnout
2024-08-06 00:00:0010-QStáhnout
2024-07-31 01:00:008-KStáhnout
2024-07-31 00:00:008-KStáhnout
2024-07-11 01:00:008-KStáhnout
2024-07-11 00:00:008-KStáhnout
2024-07-09 01:00:008-KStáhnout
2024-07-09 00:00:008-KStáhnout
2024-07-08 01:00:008-KStáhnout
2024-07-08 00:00:008-KStáhnout
2024-06-27 01:00:008-KStáhnout
2024-06-27 00:00:008-KStáhnout
2024-06-03 01:00:008-KStáhnout
2024-06-03 00:00:008-KStáhnout
2024-05-31 01:00:008-KStáhnout
2024-05-31 00:00:008-KStáhnout
2024-05-07 01:00:008-KStáhnout
2024-05-07 01:00:0010-QStáhnout
2024-05-07 00:00:008-KStáhnout
2024-05-07 00:00:0010-QStáhnout
2024-03-12 00:00:008-KStáhnout
2024-03-11 23:00:008-KStáhnout
2024-02-20 00:00:008-KStáhnout
2024-02-20 00:00:0010-KStáhnout
2024-02-19 23:00:008-KStáhnout
2024-02-19 23:00:0010-KStáhnout
2024-01-23 00:00:008-KStáhnout
2024-01-22 23:00:008-KStáhnout
2024-01-19 00:00:008-KStáhnout
2024-01-18 23:00:008-KStáhnout
2024-01-16 00:00:008-KStáhnout
2024-01-15 23:00:008-KStáhnout
2024-01-12 00:00:008-KStáhnout
2024-01-11 23:00:008-KStáhnout
2023-12-04 00:00:008-KStáhnout
2023-12-03 23:00:008-KStáhnout
2023-11-17 00:00:008-KStáhnout
2023-11-16 23:00:008-KStáhnout
2023-11-07 00:00:008-KStáhnout
2023-11-07 00:00:0010-QStáhnout
2023-11-06 23:00:008-KStáhnout
2023-11-06 23:00:0010-QStáhnout
2023-10-27 01:00:008-KStáhnout
2023-10-27 00:00:008-KStáhnout
2023-10-24 01:00:008-KStáhnout
2023-10-24 00:00:008-KStáhnout
2023-10-23 01:00:008-KStáhnout
2023-10-23 00:00:008-KStáhnout
2023-09-26 01:00:008-KStáhnout
2023-09-26 00:00:008-KStáhnout
2023-08-10 01:00:008-KStáhnout
2023-08-10 01:00:0010-QStáhnout
2023-08-10 00:00:008-KStáhnout
2023-08-10 00:00:0010-QStáhnout
2023-07-03 01:00:008-KStáhnout
2023-07-03 00:00:008-KStáhnout
2023-06-30 01:00:008-KStáhnout
2023-06-30 00:00:008-KStáhnout
2023-06-09 01:00:008-KStáhnout
2023-06-09 00:00:008-KStáhnout
2023-06-06 01:00:008-KStáhnout
2023-06-06 00:00:008-KStáhnout
2023-05-16 01:00:008-KStáhnout
2023-05-16 00:00:008-KStáhnout
2023-05-09 01:00:008-KStáhnout
2023-05-09 01:00:0010-QStáhnout
2023-05-09 00:00:008-KStáhnout
2023-05-09 00:00:0010-QStáhnout
2023-04-27 01:00:008-KStáhnout
2023-04-27 00:00:008-KStáhnout
2023-04-24 01:00:008-KStáhnout
2023-04-24 00:00:008-KStáhnout
2023-03-13 00:00:008-KStáhnout
2023-03-12 23:00:008-KStáhnout
2023-03-07 00:00:008-KStáhnout
2023-03-07 00:00:0010-KStáhnout
2023-03-06 23:00:008-KStáhnout
2023-03-06 23:00:0010-KStáhnout
2022-11-08 00:00:008-KStáhnout
2022-11-08 00:00:0010-QStáhnout
2022-11-07 23:00:008-KStáhnout
2022-11-07 23:00:0010-QStáhnout
2022-09-19 01:00:008-KStáhnout
2022-09-19 00:00:008-KStáhnout
2022-09-14 01:00:008-KStáhnout
2022-09-14 00:00:008-KStáhnout
2022-08-15 01:00:008-KStáhnout
2022-08-15 01:00:0010-QStáhnout
2022-08-15 00:00:008-KStáhnout
2022-08-15 00:00:0010-QStáhnout
2022-07-27 01:00:008-KStáhnout
2022-07-27 00:00:008-KStáhnout
2022-06-10 01:00:008-KStáhnout
2022-06-10 00:00:008-KStáhnout
2022-05-10 01:00:008-KStáhnout
2022-05-10 01:00:0010-QStáhnout
2022-05-10 00:00:008-KStáhnout
2022-05-10 00:00:0010-QStáhnout
2022-04-06 01:00:008-KStáhnout
2022-04-06 00:00:008-KStáhnout
2022-03-18 00:00:0010-KStáhnout
2022-03-17 23:00:0010-KStáhnout
2022-03-15 00:00:008-KStáhnout
2022-03-14 23:00:008-KStáhnout
2021-11-15 00:00:008-KStáhnout
2021-11-15 00:00:0010-QStáhnout
2021-11-14 23:00:008-KStáhnout
2021-11-14 23:00:0010-QStáhnout
2021-08-10 01:00:008-KStáhnout
2021-08-10 01:00:0010-QStáhnout
2021-08-10 00:00:008-KStáhnout
2021-08-10 00:00:0010-QStáhnout
2021-07-12 01:00:008-KStáhnout
2021-07-12 00:00:008-KStáhnout
2021-06-28 01:00:008-KStáhnout
2021-06-28 00:00:008-KStáhnout
2021-06-14 01:00:008-KStáhnout
2021-06-14 00:00:008-KStáhnout
2021-05-10 01:00:008-KStáhnout
2021-05-10 01:00:0010-QStáhnout
2021-05-10 00:00:008-KStáhnout
2021-05-10 00:00:0010-QStáhnout
2021-03-23 00:00:008-KStáhnout
2021-03-23 00:00:0010-KStáhnout
2021-03-22 23:00:008-KStáhnout
2021-03-22 23:00:0010-KStáhnout
2021-02-17 00:00:008-KStáhnout
2021-02-16 23:00:008-KStáhnout
2021-01-21 00:00:008-KStáhnout
2021-01-20 23:00:008-KStáhnout
2021-01-19 00:00:008-KStáhnout
2021-01-18 23:00:008-KStáhnout
2021-01-11 00:00:008-KStáhnout
2021-01-10 23:00:008-KStáhnout
2020-11-12 00:00:008-KStáhnout
2020-11-12 00:00:0010-QStáhnout
2020-11-11 23:00:008-KStáhnout
2020-11-11 23:00:0010-QStáhnout
2020-09-24 01:00:008-KStáhnout
2020-09-24 00:00:008-KStáhnout
2020-08-12 01:00:008-KStáhnout
2020-08-12 01:00:0010-QStáhnout
2020-08-12 00:00:008-KStáhnout
2020-08-12 00:00:0010-QStáhnout
2020-08-04 01:00:008-KStáhnout
2020-08-04 00:00:008-KStáhnout
2020-06-30 01:00:008-KStáhnout
2020-06-30 00:00:008-KStáhnout
2020-06-22 01:00:008-KStáhnout
2020-06-22 00:00:008-KStáhnout
2020-06-16 01:00:008-KStáhnout
2020-06-16 00:00:008-KStáhnout
2020-05-12 01:00:008-KStáhnout
2020-05-12 01:00:0010-QStáhnout
2020-05-12 00:00:008-KStáhnout
2020-05-12 00:00:0010-QStáhnout
2020-04-07 01:00:008-KStáhnout
2020-04-07 00:00:008-KStáhnout
2020-03-24 00:00:008-KStáhnout
2020-03-24 00:00:0010-KStáhnout
2020-03-23 23:00:008-KStáhnout
2020-03-23 23:00:0010-KStáhnout
2020-03-17 00:00:008-KStáhnout
2020-03-16 23:00:008-KStáhnout
2020-03-11 00:00:008-KStáhnout
2020-03-10 23:00:008-KStáhnout
2020-01-13 00:00:008-KStáhnout
2020-01-12 23:00:008-KStáhnout
2019-12-18 00:00:008-KStáhnout
2019-12-17 23:00:008-KStáhnout
2019-11-20 00:00:008-KStáhnout
2019-11-19 23:00:008-KStáhnout
2019-11-13 00:00:008-KStáhnout
2019-11-13 00:00:0010-QStáhnout
2019-11-12 23:00:008-KStáhnout
2019-11-12 23:00:0010-QStáhnout
2019-10-07 01:00:008-KStáhnout
2019-10-07 00:00:008-KStáhnout
2019-08-12 01:00:008-KStáhnout
2019-08-12 01:00:0010-QStáhnout
2019-08-12 00:00:008-KStáhnout
2019-08-12 00:00:0010-QStáhnout
2019-05-28 01:00:008-KStáhnout
2019-05-28 00:00:008-KStáhnout
preloader